IMCC vs LYRA
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
IMCC exhibits severe financial distress, characterized by a Piotroski F-Score of 4/9 and the absence of a Graham Number or Altman Z-Score due to negative equity (Price/Book: -0.80). While the company has shown recent revenue growth of 17.6% and a series of EPS 'beats,' these are marginal improvements on a foundation of deep losses and negative margins. The catastrophic 5-year price decline of 99.9% and a current ratio of 0.67 indicate a high risk of insolvency and a lack of investor confidence.
LYRA is in a state of severe financial distress, evidenced by a critical Piotroski F-Score of 1/9 and a negative Price-to-Book ratio of -0.25, indicating negative shareholder equity. The company has experienced a catastrophic revenue collapse of -96.70% YoY and an extreme operating margin of -98,728.57%. With a 52-week high of $37.50 now trading at $0.65, the stock has lost nearly all its value. The combination of negative equity, vanishing revenue, and bearish insider activity suggests a high risk of insolvency.
Compare Another Pair
Related Comparisons
IMCC vs LYRA: Head-to-Head Comparison
This page compares IM Cannabis Corp. (IMCC) and Lyra Therapeutics, Inc. (LYRA) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.